Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00735306 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00735306 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 12 participants.
The verdict
NCT00735306, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary purpose of this trial is to define the maximum tolerated and/or recommended phase II dose of the combination of Avastin and Tarceva in patients undergoing radiation therapy for carcinoma of the pancreas. An additional primary objective is to describe the frequency and nature of grade III/IV and grade I/II toxicities associated with this regimen. Secondary objectives include describing 1-year disease-free survival and overall survival rates as well as to estimate clinical and pathologic complete response rates associated with this regimen.
Interventions
- RADIATION Radiation Therapy
- DRUG Avastin
- DRUG Tarceva
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00735306
The ClinicalTrials.gov registry entry for NCT00735306 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT00735306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00735306 about?
NCT00735306 is a clinical study titled "Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma". The primary purpose of this trial is to define the maximum tolerated and/or recommended phase II dose of the combination of Avastin and Tarceva in patients undergoing radiation therapy for carcinoma of the pancreas. An additional primary objective is to describe the frequency and nature of grade III...
What is the current status of trial NCT00735306?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-07. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00735306?
The interventions under investigation include: Radiation Therapy (RADIATION), Avastin (DRUG), Tarceva (DRUG).
Who is sponsoring clinical trial NCT00735306?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.